Expertise in
17
conditions

Dr. Leon H. Kircik

Dermatology
Clinical Pathology Associates
1425 Madison Ave, 
New York, NY 
Accepting New Patients
Referral may be required
Before you request
Expertise in
17
conditions
Clinical Pathology Associates
1425 Madison Ave, 
New York, NY 

Overview

Leon Kircik is a Dermatologist practicing medicine in New York, New York.

Dr. Kircik is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Acne, Plaque Psoriasis, Atopic Dermatitis, and Psoriasis.

He is actively involved in clinical research, co-authoring 364 peer reviewed articles and participating in 17 clinical trials. Dr. Kircik is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in KY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Clinical Pathology Associates
1425 Madison Ave, New York, NY 10029
Other Locations
MSSM-Optical Shop
17 E 102nd St, New York, NY 10029

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug, Biological
Study Drug: CDX-0159
Study Phase: Phase 1
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
View 9 Less Clinical Trials

364 Total Publications

Treatment Adherence in Patients With Acne Vulgaris: A Narrative Review.
Treatment Adherence in Patients With Acne Vulgaris: A Narrative Review.
Journal: Journal of drugs in dermatology : JDD
Published: September 04, 2026
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required
Before you request

Office

1275 York Ave Ste 407, 
New York, NY 
 (1.8 miles away)
646-888-6018
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Patricia Myskowski is a Dermatologist practicing medicine in New York, New York. Dr. Myskowski is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses T-Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), and Lymphomatoid Papulosis. Dr. Myskowski is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required
Before you request

Israel Englander Department Of Dermatology At 211 East 80th Street

211 E 80th St # 2, 
New York, NY 
 (1.1 miles away)
347-378-5278
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Alexis is a Dermatologist practicing medicine in New York, New York. Dr. Alexis is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Melasma, Acne, Atopic Dermatitis, and Vitiligo. Dr. Alexis is currently accepting new patients.

Expertise in
9
conditions
Dr. Aimee S. Payne
Dermatology
Expertise in
9
conditions
Dr. Aimee S. Payne
Dermatology
Referral may be required
Before you request

CUIMC/Herbert Irving Pavilion

161 Fort Washington Ave, 
New York, NY 
 (3.6 miles away)
914-768-8691
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aimee Payne is a Dermatologist practicing medicine in New York, New York. Dr. Payne is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Pemphigus, Pemphigus Vulgaris, Pemphigus Foliaceus, and Bullous Pemphigoid. Dr. Payne is currently accepting new patients.

Frequently Asked Questions about Dr. Leon H. Kircik

How do I make an appointment with Dr. Leon H. Kircik?

You can book an appointment with Dr. Leon H. Kircik by calling their office at 212-659-9530. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Leon H. Kircik a top-rated expert for Acne?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Leon H. Kircik is classified as an Elite expert for Acne, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Leon H. Kircik specialize in?

While Dr. Leon H. Kircik is a Dermatology, they have specific expertise in Acne, Plaque Psoriasis, and Atopic Dermatitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Leon H. Kircik participate in research or clinical trials?

Yes. Dr. Leon H. Kircik has published 364 articles and abstracts on conditions like Acne. You can view a list of Dr. Leon H. Kircik's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Leon H. Kircik accept my insurance?

Dr. Leon H. Kircik accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 212-659-9530 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kircik's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile